Science News
from research organizations

New insights into cancer treatment

Date:
March 15, 2011
Source:
VIB (the Flanders Institute for Biotechnology)
Summary:
A researcher strongly argues against the use of Cop1-inhibitory drugs.
Share:
       
FULL STORY

Jean-Christophe Marine (VIB, K.U.Leuven) strongly argues against the use of Cop1-inhibitory drugs. The protein Cop1 has -for a long time -- been seen as an attractive drug target for cancer. But Jean-Christophe Marine found out that Cop1 acts as a tumor suppressor, and thus inhibits tumor formation. His new data will have direct implications for the development of cancer drug targets.

Tumorigenesis: loss of control

Tumors form when control over the cell division is lost; a process that could be compared to losing control over the speed of your car. Two main players are involved; oncogenes which could be compared to the gas pedal of the car. A defective oncogene would be analogous to a gas pedal that is stuck in the 'on' position. In such a situation the tumor suppressor genes function as the brakes of the car -- they keep the cell from dividing even in response to oncogene activation. If the brakes fail, the car goes out of control; similarly, when something goes wrong with the tumor suppressor genes, cell division gets out of control.

Cop1: brake or gas pedal?

Although Cop1 has been implicated in tumorigenesis, its precise role has remained a conundrum. Biochemical studies had shown that Cop1 promotes the degradation of target proteins. These studies, however, have yielded conflicting results leaving an open question as to whether Cop1 degrade tumor suppressors or oncogenes.

Several studies have indeed indicated that Cop1 favors tumorigenesis by inactivating one of the key tumor suppressors, p53. Accordingly, Cop1 overexpression was reported in breast and ovarian adenocarcinomas. Cop1 was therefore considered to be an oncogene and an attractive drug target for cancer therapy.

Solving the Cop1 puzzle has major implications for cancer drug development

Jean-Christophe Marine and his team now show that it is quite the opposite, namely that Cop1 functions as a tumor suppressor. Using an innovative mouse genetic engineering approach the VIB scientists generated Cop1-deficient mice. They show that these mice are highly tumor prone. They also show that Cop1 regulates the stability of the oncogene c-Jun and that deficiency of Cop1 stimulates cell proliferation of mouse and human cancer cells. In keeping with these data, they provide evidence that Cop1 expression is lost in various human cancers. Crucially for cancer therapy, they could find no evidence for the previously suggested role of Cop1 in the regulation of the tumor suppressor p53.

Jean-Christophe Marine said, 'Our findings strongly argue against the use of Cop1-inhibitory drugs in cancer therapy.'


Story Source:

The above story is based on materials provided by VIB (the Flanders Institute for Biotechnology). Note: Materials may be edited for content and length.


Journal Reference:

  1. Domenico Migliorini, Sven Bogaerts, Dieter Defever, Rajesh Vyas, Geertrui Denecker, Enrico Radaelli, Aleksandra Zwolinska, Vanessa Depaepe, Tino Hochepied, William C. Skarnes, Jean-Christophe Marine. Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI45784

Cite This Page:

VIB (the Flanders Institute for Biotechnology). "New insights into cancer treatment." ScienceDaily. ScienceDaily, 15 March 2011. <www.sciencedaily.com/releases/2011/03/110315103749.htm>.
VIB (the Flanders Institute for Biotechnology). (2011, March 15). New insights into cancer treatment. ScienceDaily. Retrieved May 26, 2015 from www.sciencedaily.com/releases/2011/03/110315103749.htm
VIB (the Flanders Institute for Biotechnology). "New insights into cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2011/03/110315103749.htm (accessed May 26, 2015).

Share This Page: